Why Are Lopinavir and Ritonavir Effective against the Newly Emerged Coronavirus 2019? Atomistic Insights into the Inhibitory Mechanisms
Top Cited Papers
- 15 April 2020
- journal article
- research article
- Published by American Chemical Society (ACS) in Biochemistry
- Vol. 59 (18), 1769-1779
- https://doi.org/10.1021/acs.biochem.0c00160
Abstract
Since the emergence of a novel coronavirus disease (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was firstly reported from Wuhan, China, to date, neither a specific vaccine nor antiviral drug against SARS-CoV-2 is available. However, a combination of two HIV-1 protease inhibitors lopinavir and ritonavir has been found to be effective against SARS-CoV, and both drugs could bind well to the SARS-CoV 3C-like protease (SARS-CoV 3CLpro). In this work, molecular complexation between each inhibitor and the SARS-CoV-2 3CLpro was studied using all-atom molecular dynamics simulations, free energy calculations and pair interaction energy analyses based on the MM/PB(GB)SA and FMO-MP2/PCM/6-31G*. Both anti-HIV drugs interacted well with the residues at the active site of the SARS-CoV-2 3CLpro. Ritonavir showed somewhat higher atomic contacts, binding efficiency and key binding residues than that of lopinavir in correspondence with slightly less water accessibility at the 3CLpro active site. In addition, only ritonavir could interact with the oxyanion hole residues N142 and G143 via two hydrogen bond formations. The interactions in terms of electrostatics, dispersion and charge transfer played an important role in the drug binding. The obtained results demonstrated how repurposed anti-HIV drugs could be used to combat COVID-19.Keywords
Funding Information
- Chulalongkorn University
- National Science and Technology Development Agency
This publication has 54 references indexed in Scilit:
- H++ 3.0: automating pK prediction and the preparation of biomolecular structures for atomistic molecular modeling and simulationsNucleic Acids Research, 2012
- Inhibitors of SARS-3CLpro: Virtual Screening, Biological Evaluation, and Molecular Dynamics Simulation StudiesJournal of Chemical Information and Modeling, 2011
- Dynamically-Driven Inactivation of the Catalytic Machinery of the SARS 3C-Like Protease by the N214A Mutation on the Extra DomainPLoS Computational Biology, 2011
- Molecular dynamic simulations analysis of ritronavir and lopinavir as SARS-CoV 3CLpro inhibitorsJournal of Theoretical Biology, 2008
- Lopinavir/ritonavir in the treatment of human immunodeficiency virus infectionExpert Opinion on Pharmacotherapy, 2005
- Development and testing of a general amber force fieldJournal of Computational Chemistry, 2004
- Synchronization of trajectories in canonical molecular-dynamics simulations: Observation, explanation, and exploitationThe Journal of Chemical Physics, 2004
- Pharmacological and therapeutic properties of ritonavir-boosted protease inhibitor therapy in HIV-infected patientsJournal of Antimicrobial Chemotherapy, 2003
- Molecular dynamics with coupling to an external bathThe Journal of Chemical Physics, 1984
- Comparison of simple potential functions for simulating liquid waterThe Journal of Chemical Physics, 1983